Seventy-two total knee arthroplasties performed in patients with haemophilia using continuous infusion
Version of Record online: 1 OCT 2012
© 2012 The Author(s). Vox Sanguinis © 2012 International Society of Blood Transfusion
Volume 104, Issue 2, pages 135–143, February 2013
How to Cite
Chevalier, Y., Dargaud, Y., Lienhart, A., Chamouard, V. and Negrier, C. (2013), Seventy-two total knee arthroplasties performed in patients with haemophilia using continuous infusion. Vox Sanguinis, 104: 135–143. doi: 10.1111/j.1423-0410.2012.01653.x
- Issue online: 17 JAN 2013
- Version of Record online: 1 OCT 2012
- Received: 8 February 2012, revised 14 August 2012, accepted 20 August 2012
- continuous infusion;
- total knee arthroplasty
Background and Objectives Total knee replacement (TKR) is the treatment of choice in case of end-stage knee arthropathy, the main complication of haemophilia. We report here a retrospective evaluation of 72 total knee replacement in 51 haemophilia A and B patients using continuous infusion of factor concentrates (CIFC).
Materials and Methods Patients were evaluated on the basis of the following efficacy and safety criteria: range of motion, surgery-related blood loss by three different methods, factor consumption and occurrence of short and long term complications.
Results Kaplan–Meier analysis showed a removal-free survival of TKRs of 88.4% 10 years after surgery. Most patients were satisfied with their prosthesis and described pain relief and improved mobility and better quality of life after surgery. The long term follow-up showed a mean range of motion at 86° with a flexion deformity of 4°. The blood loss differed significantly according to the method used for measurement. No life-threatening bleeding occurred. Twenty six haematomas (36.1%) and 2 haemarthroses (2.7%) occurred in 38.8% of cases during the first three postoperative weeks, with no significant impact on the orthopaedic outcome. The average factor consumption during hospitalization was 79 IU/kg/day for patients with haemophilia A and 99 IU/kg/day for patients with haemophilia B. Infections occurred in 4.1% of patients. One patient with severe haemophilia A developed an inhibitor.
Conclusions The multidisciplinary approach and the homogeneous management of our large cohort allowed the achievement of excellent functional results. Our results confirmed previously reported data on the safety and efficacy of CIFC in situations requiring intensive factor replacement, such as TKR surgery.